Actionable news
0
All posts from Actionable news
Actionable news in ABUS: ARBUTUS BIOPHARMA CORPORATION COMMON STOCK,

Termination of a Material Definitive

On October 1, 2015, we received formal notification of contract termination from the U.S. Department of Defense that our contract with the Department of Defense for the development of TKM-Ebola, an RNAi therapeutic utilizing our lipid nanoparticle technology to treat Ebola virus infection, was terminated, as expected, by the Department of Defense subject to the completion of our post-termination obligations contained therein.

As disclosed on...


More